EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CELF2 Sustains a Proliferating/OLIG2+ Glioblastoma Cell Phenotype via the Epigenetic Repression of SOX3

Laurent Turchi iD, Nathalie Sakakini, Gaelle Saviane, Béatrice Polo, Mirca Saras Saurty-Seerunghen iD, Mathieu Gabut iD, Corine Auge Gouillou, Vincent Guerlais, Claude Pasquier iD, Marie Luce Vignais iD, Fabien Almairac iD, Hervé Chneiweiss und 3 weitere

Cancers · 18.10.2023 · 15 (20) · 5038

DOI: 10.3390/cancers15205038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 18.10.2023. Verfasst von Laurent Turchi und 14 weiteren Autor:innen. Beteiligte Einrichtung: CNRS, INSERM, Institut de Biologie Valrose, Team INSERM "Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity", Université Côte D'Azu…. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: French National Cancer Institute, association Dimitri Bessière, Fondation ARC pour la Recherche sur le Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastomas (GBs) are incurable brain tumors. The persistence of aggressive stem-like tumor cells after cytotoxic treatments compromises therapeutic efficacy, leading to GBM recurrence. Forcing the GBM cells to irreversibly abandon their aggressive stem-like phenotype may offer an alternative to conventional cytotoxic treatments. Here, we show that the RNA binding protein CELF2 is strongly expressed in mitotic and OLIG2-positive GBM cells, while it is downregulated in differentiated and non-mitotic cells by miR-199a-3p, exemplifying GBM intra-tumor heterogeneity. Using patient-derived cells and human GBM samples, we demonstrate that CELF2 plays a key role in maintaining the proliferative/OLIG2 cell phenotype with clonal and tumorigenic properties. Indeed, we show that CELF2 deficiency in patient-derived GSCs drastically reduced tumor growth in the brains of nude mice. We further show that CELF2 promotes TRIM28 and G9a expression, which drive a H3K9me3 epigenetic profile responsible for the silencing of the SOX3 gene. Thus, CELF2, which is positively correlated with OLIG2 and Ki67 expression in human GBM samples, is inversely correlated with SOX3 and miR-199a-3p. Accordingly, the invalidation of SOX3 in CELF2-deficient patient-derived cells rescued proliferation and OLIG2 expression. Finally, patients expressing SOX3 above the median level of expression tend to have a longer life expectancy. CELF2 is therefore a crucial target for the malignant potential of GBM and warrants attention when developing novel anticancer strategies.

Schlagwörter

Stichwörter der Autor:innen

CELF2H3K9me3OLIG2RNA binding proteincancer stem cellsepigeneticglioblastoma

Autor:innen und Institutionen

  • CNRS, INSERM, Institut de Biologie Valrose, Team INSERM "Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity", Université Côte D'Azur, 06107 Nice, France.
  • DRCI, CHU de Nice, 06107 Nice, France.
  • CNRS UMR8246, INSERM U1130, Neuroscience Paris Seine-IBPS Laboratory, Team Glial Plasticity and NeuroOncology, Sorbonne Université, 75252 Paris, France.
  • Stemness in Gliomas Laboratory, Cancer Initiation and Tumoral Cell Identity (CITI) Department, INSERM 1052, CNRS 5286, Centre Léon Bérard, 69008 Lyon, France.
  • Cancer Research Center of Lyon 1, Université Claude Bernard Lyon 1, 69100 Villeurbanne, France.
  • UMR 1253, iBrain, Inserm, Université de Tours, 37000 Tours, France.

ORCID-Profile: Laurent Turchi, Mirca Saras Saurty-Seerunghen, Mathieu Gabut, Claude Pasquier, Marie Luce Vignais, Fabien Almairac, Marie-Pierre Junier, Thierry Virolle

Förderung

  • French National Cancer Institute
  • association Dimitri Bessière
  • Fondation ARC pour la Recherche sur le Cancer
  • Inserm
  • Association Sauvons Laura
  • Association Dimitri Bessières
  • Agence Nationale pour la Recherche
  • Association pour la Recherche sur le Cancer

Zitieren

APA

Turchi, L., Sakakini, N., Saviane, G., Polo, B., Saurty-Seerunghen, M. S., Gabut, M., Gouillou, C. A., Guerlais, V., Pasquier, C., Vignais, M. L., Almairac, F., Chneiweiss, H., Junier, M. P., Burel-Vandenbos, F., & Virolle, T. (2023). CELF2 Sustains a Proliferating/OLIG2+ Glioblastoma Cell Phenotype via the Epigenetic Repression of SOX3. Cancers, 15(20), 5038. https://doi.org/10.3390/cancers15205038

Vancouver

Turchi L, Sakakini N, Saviane G, Polo B, Saurty-Seerunghen MS, Gabut M, et al. CELF2 Sustains a Proliferating/OLIG2+ Glioblastoma Cell Phenotype via the Epigenetic Repression of SOX3. Cancers. 2023;15(20):5038. doi:10.3390/cancers15205038

BibTeX
@article{Turchi2023,
  author = {Turchi, Laurent and Sakakini, Nathalie and Saviane, Gaelle and Polo, Béatrice and Saurty-Seerunghen, Mirca Saras and Gabut, Mathieu and Gouillou, Corine Auge and Guerlais, Vincent and Pasquier, Claude and Vignais, Marie Luce and Almairac, Fabien and Chneiweiss, Hervé and Junier, Marie-Pierre and Burel-Vandenbos, Fanny and Virolle, Thierry},
  title = {CELF2 Sustains a Proliferating/OLIG2+ Glioblastoma Cell Phenotype via the Epigenetic Repression of SOX3},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {20},
  pages = {5038},
  doi = {10.3390/cancers15205038}
}
Kostenlos starten →